SZM679

• CAT Number: I042389
• CAS Number: 3027645-52-6
• Molecular Formula: C27H18F5N3O5S
• Molecular Weight: 591.51
• Purity: ≥95%
• Synonyms: N-[5-fluoro-6-[4-fluoro-3-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-yl]-3-oxocyclobutane-1-carboxamide
• InChI: InChI=1S/C27H18F5N3O5S/c28-18-5-4-16(10-20(18)33-24(37)7-13-2-1-3-17(6-13)40-27(30,31)32)39-22-12-23-21(11-19(22)29)34-26(41-23)35-25(38)14-8-15(36)9-14/h1-6,10-12,14H,7-9H2,(H,33,37)(H,34,35,38)
• InChIKey: OFQHMPFSITXRSS-UHFFFAOYSA-N
• SMILES: C1C(CC1=O)C(=O)NC2=NC3=CC(=C(C=C3S2)OC4=CC(=C(C=C4)F)NC(=O)CC5=CC(=CC=C5)OC(F)(F)F)F

SZM679 (Cat No.: I042389) is a selective and potent small-molecule inhibitor targeting the KRAS G12D mutation, a common oncogenic driver in pancreatic, colorectal, and non-small cell lung cancers. By covalently binding to the KRAS G12D mutant, SZM679 blocks downstream signaling pathways such as MAPK and PI3K-AKT, suppressing tumor cell proliferation and survival. It demonstrates high specificity with minimal activity against wild-type KRAS, making it a valuable tool in precision oncology. SZM679 supports the development of targeted therapies for KRAS G12D-driven cancers.

Reference

[1]. Sun Y, et, al. Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease. J Med Chem. 2022 Nov 10;65(21):14957-14969.
[Content Brief]